333 filings
Page 2 of 17
8-K
27npttb n20tl
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm
8-K
aq343
18 Dec 23
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
4:15pm
8-A12B/A
4pc 5ceu1nbpo
18 Dec 23
Registration of securities on exchange (amended)
4:05pm
8-K
e208xewbul
18 Dec 23
Entry into a Material Definitive Agreement
4:01pm
8-K
njz50ls858b319u0vz
29 Nov 23
Other Events
4:00pm
8-K
vzji d98w
27 Nov 23
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
4:00pm
8-K
abwsl
15 Nov 23
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
4:13pm
8-K
f22fhxwwjfk5f8kxyx
1 Nov 23
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
4:13pm
8-K
x1wspkfnjb09t
31 Oct 23
Regulation FD Disclosure
4:25pm
8-K
3as x3lful
17 Oct 23
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
7:03pm
8-K
fe2414rfoim uzx
7 Sep 23
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
9:10am
8-K
izkbg kl354xec
5 Sep 23
Other Events
4:00pm
8-K
dupb6jktcrbrakb3qt3
16 Aug 23
Entry into a Material Definitive Agreement
4:41pm
424B5
9femm
16 Aug 23
Prospectus supplement for primary offering
4:39pm
8-K
s7d8aedy6vctu97
8 Aug 23
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
4:01pm
8-K
mhs2we
2 Aug 23
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
6:02am
8-K
7micoo8s9u6vzwnehhja
31 Jul 23
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
6:02pm
8-K
6wrebwr bc0rp4
27 Jul 23
Other Events
4:43pm